A Randomized, Double-Blind, Sponsor Unblinded, Placebo Controlled, 5-Way, Crossover Study To Evaluate The Effects Of Single Oral Administrations of PF-05212377 (SAM-760), A 5-HT6 Antagonist, On Scopolamine Induced Deficits In Psychomotor And Cognitive Function In Healthy Young Adults.

Trial Profile

A Randomized, Double-Blind, Sponsor Unblinded, Placebo Controlled, 5-Way, Crossover Study To Evaluate The Effects Of Single Oral Administrations of PF-05212377 (SAM-760), A 5-HT6 Antagonist, On Scopolamine Induced Deficits In Psychomotor And Cognitive Function In Healthy Young Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2011

At a glance

  • Drugs Donepezil; PF 5212377; Scopolamine
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 26 Oct 2011 Actual end date added 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 26 Oct 2011 Actual initiation date added 1 Apr 2011 as reported by ClinicalTrials.gov.
    • 26 Oct 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top